Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash
Theravance Biopharma reported Q2 2026 revenue of $20.7M, all from its Viatris collaboration, up 11% YoY. GAAP net loss was $5.9M. Cash and marketable securities were $387.7M at June 30, 2026. The company said a Zymeworks acquisition is expected to close in H2 2026, and it cited restructuring cost savings.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term operating trajectory (expense run-rate savings) and balance-sheet resilience (cash near $388M, no debt), while also repricing deal-close risk and the value of the contingent value right.
Market read
Fresh quarterly financials plus a disclosed acquisition structure and expected cost-savings run-rate provide actionable inputs for both fundamentals and deal-arbitrage positioning.
What to watch
The contingent value right tied to future ampreloxetine monetization could be a major driver of realized value, but the article does not quantify probability or timing.
Background
Theravance Biopharma’s Q2 2026 update centers on Viatris collaboration revenue tied to YUPELRI economics, alongside restructuring to reduce operating expenses and a pending acquisition by Zymeworks.
Ticker impact
Theravance Biopharma reported Q2 2026 results, including $20.7M revenue from the Viatris collaboration and a GAAP net loss of $5.9M.
Likely two-sided reaction: modest support from restructuring-driven expense reduction and cash, offset by GAAP loss and deal execution risk.
The article provides concrete quarterly financials and deal terms (cash price plus contingent value right) plus cost-savings expectations, which can move valuation and risk premia into the close window.
Market effects
Highlights ongoing commercialization economics for respiratory assets (YUPELRI) and the importance of collaboration revenue streams in biotech profitability.
No clear regional spillover beyond US-listed biotech sentiment.
Deal and collaboration dynamics may influence cross-border biotech M&A expectations, but no direct global macro linkage is stated.
Counterpoint
GAAP net loss and reliance on a single collaboration revenue stream may limit the durability of the quarter’s improvement despite expense cuts.
Key entities
- companyTheravance Biopharma
Reported Q2 2026 revenue of $20.7M from Viatris collaboration, GAAP net loss of $5.9M, and cash of $387.7M at June 30, 2026.
- companyViatris
Collaboration partner whose reported U.S. net sales for YUPELRI were $70.7M in Q2 2026, implying Theravance’s 35% share.
- companyZymeworks
Agreed to acquire Theravance for $17.00 per share in cash plus a contingent value right tied to future ampreloxetine monetization.
- companyRoyalty Pharma
Royalty Pharma is referenced as the counterparty for a TRELEGY royalty milestone payment of $100M targeted in 2026.
